Text size Nasdaq-listed Antares Pharma is being bought by Halozyme Therapeutics in a deal valued at $960 million. Michael Nagle/Bloomberg Shares of Antares Pharma surged more than 47% in premarket tra...
Text size Nasdaq-listed Antares Pharma is being bought by Halozyme Therapeutics in a deal valued at $960 million. Michael Nagle/Bloomberg Shares of Antares Pharma surged more than 47% in premarket tra...